#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that New York’s disproportionate focus on recreational cannabis over medical infrastructure has created significant gaps in regulated medical access, standardized dosing information, and clinical guidance for patients seeking cannabis for therapeutic purposes. The “messy middle” described in this review directly affects prescribing practices, as providers lack consistent evidence frameworks and patient education resources that a mature medical program would typically provide. These implementation delays mean clinicians must navigate patient requests for cannabis therapeutics without the institutional support systems and outcome data that would enable evidence-based recommendations in clinical settings.
New York’s five-year experience with cannabis legalization reveals ongoing tensions between recreational market expansion, medical application development, and regulatory implementation challenges that continue to shape clinical practice and patient access. The regulatory framework has struggled to keep pace with both the growing body of clinical evidence supporting cannabis for specific conditions and the practical realities of a rapidly developing commercial market. These gaps between policy intent, clinical evidence, and market dynamics have created a complex landscape where healthcare providers must navigate evolving guidance while patients seek clarity on therapeutic uses and safety profiles.
“What we’re seeing in New York is a public health failure dressed up as regulatory success: we’ve built a recreational market that’s outpaced our medical infrastructure by years, which means patients who actually need cannabis for symptom management are competing with recreational consumers for limited medical access while their clinicians remain undertrained. The messy middle isn’t a transition phase we’ll clean up later—it’s the predictable result of prioritizing tax revenue over clinical integration, and every month we delay proper medical credentialing and education costs us patients who could benefit.”
🔬 While cannabis beverages represent an emerging consumer preference in regulated markets, the limited data presented here requires careful interpretation before clinical adoption. The comparison to “traditional” consumption methods lacks specificity about which methods, dosing equivalence, pharmacokinetic differences, and whether participants were matched on baseline cannabis experience or other relevant variables. Adult self-selection into THC or CBD beverages introduces substantial selection bias—users choosing this format may differ systematically in age, motivation, risk tolerance, or concurrent substance use in ways that confound any observed outcomes. Until peer-reviewed publication provides transparent methodology, outcome definitions, and adjustment for relevant confounders, clinicians should remain cautious about recommending cannabis beverages as a preferred therapeutic option. In practice, patients inquiring about cannabis should still receive counseling based on the existing evidence base for cannabis in specific conditions, with the understanding that beverage formulations add variables around absorption, onset time, and overdose risk that warrant
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: